PARTOW KEBRIAEI to T-Lymphocytes
This is a "connection" page, showing publications PARTOW KEBRIAEI has written about T-Lymphocytes.
Connection Strength
1.925
-
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
Score: 0.287
-
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
Score: 0.223
-
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 2015 Apr; 50(4):493-8.
Score: 0.201
-
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012 May; 23(5):444-50.
Score: 0.163
-
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed). 2012 01 01; 4(2):520-31.
Score: 0.162
-
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
Score: 0.062
-
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
Score: 0.058
-
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1948-54.
Score: 0.052
-
Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1714-20.
Score: 0.052
-
Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies. Curr Hematol Malig Rep. 2015 Jun; 10(2):76-85.
Score: 0.051
-
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014 Jan; 257(1):181-90.
Score: 0.047
-
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 2013; 8(5):e64138.
Score: 0.045
-
CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep. 2013 Mar; 8(1):60-70.
Score: 0.044
-
Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013 Feb; 36(2):112-23.
Score: 0.044
-
Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013 Feb 01; (72):e50070.
Score: 0.044
-
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
Score: 0.042
-
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012 Jun 14; 119(24):5697-705.
Score: 0.042
-
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat. 2012; 22(6):1206-19.
Score: 0.041
-
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011 May 15; 71(10):3516-27.
Score: 0.039
-
A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices. 2010 Oct; 12(5):855-63.
Score: 0.037
-
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010 May 15; 70(10):3915-24.
Score: 0.036
-
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010 Apr; 21(4):427-37.
Score: 0.036
-
Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16.
Score: 0.023
-
Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead. Blood Adv. 2023 07 25; 7(14):3350-3360.
Score: 0.023
-
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 04; 29(4):228-239.
Score: 0.022
-
Chimeric antigen receptor T-cell therapy toxicities. Br J Clin Pharmacol. 2021 06; 87(6):2414-2424.
Score: 0.018
-
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22.
Score: 0.012
-
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013 Aug 22; 122(8):1341-9.
Score: 0.011
-
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
Score: 0.009